Clinical trials: in Panama
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company
Herpes Simplex
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics…
- Trial name
- NCT00098059
- Testing
- Famciclovir
- Where
- 13 sites in United States, Panama
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Human Immunodeficiency Virus - Type 1
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients…
- Trial name
- ODIN (NCT00524368)
- Testing
- Darunavir (DRV), Ritonavir (rtv)
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 590 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Neoplasms
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or…
- Trial name
- SUN 1064 (NCT00393939)
- Testing
- Sunitinib malate, Taxotere
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 594 people
- Sponsor
- Pfizer
Diaper Rash
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
The purpose of this study is to determine whether repeated use of 0.25% miconazole nitrate ointment in newborns and infants with a yeast infection in the diaper area causes the yeast to become resistant to the drug.
- Trial name
- NCT00702507
- Testing
- 0.25 % Miconazole Nitrate Ointment
- Where
- 8 sites in United States, Dominican Republic and 2 more
- Volunteers
- 200 people
- Sponsor
- Stiefel, a GSK Company
Anemia
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia.
- Trial name
- NCT00090753
- Testing
- Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta
- Where
- 249 sites in United States, Australia and 25 more
- Volunteers
- 1,228 people
- Sponsor
- Hoffmann-La Roche
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV.
- Trial name
- NCT00272779
- Testing
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet
- Where
- 79 sites in United States, Argentina and 27 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Candidemia, Invasive Candidiasis
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
- Trial name
- NCT00548262
- Testing
- Anidulafungin, Voriconazole
- Where
- 13 sites in Brazil, Chile and 3 more
- Volunteers
- 54 people
- Sponsor
- Pfizer
Bacterial Infections, Diabetic Foot
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
- Conditions
- Bacterial Infections, Diabetic Foot, Osteomyelitis
- Trial name
- NCT00366249
- Testing
- Tigecycline, Ertapenem
- Where
- 211 sites in United States, Argentina and 37 more
- Volunteers
- 1,061 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer